Gen1E Lifesciences
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.
Gen1E Lifesciences has raised $17.0M across 1 round. Its most recent round was a Series Unknown of $17.0M in Dec 2022. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Gen1E Lifesciences is featured in
Similar companies
Verisoul is a company that designs a decentralized platform with artificial intelligence, aiming to aid businesses in combating the presence of fraudulent users. By merging anonymity and accountability, Verisoul collaborates with Web3 developers to enable them in identifying reliable users while distinguishing them from scammers, bots, and imposters.
Model ML is an AI tool that improves workflows for investment banks and private equity firms by integrating multiple data sources for research and due diligence, with the goal of revolutionizing the finance industry with a more efficient AI workspace.
Apptronik fabricates and plans human-focused mechanical technology frameworks.
Momentic allows developers to deploy AI agents to test the complete functionality of web applications by simply describing user flows in a natural language.
The company Harmonic creates Mathematical Superintelligence (MSI), a cutting-edge artificial intelligence system grounded in mathematical principles to ensure precision and eliminate errors.
Scale Social is an AI-powered marketing platform that automates capturing, curating, and distributing customer-generated content. It is specifically designed to help small businesses drive growth through authentic, high-impact digital marketing.
Federato's RiskOps underwriting platform for insurance carriers, MGAs and MGUs provides real-time risk selection and portfolio insights to empower underwriters to balance their book of business and make better underwriting decisions.
Kalshi is a financial exchange that is regulated by the government and allows investors to trade based on their predictions of future events. The markets offered by Kalshi cover various topics such as economics, international affairs, media, entertainment, climate, and public health. Unlike traditional instruments like stocks or bonds, Kalshi's markets are more specific, giving investors direct exposure to events and trends they are interested in. For example, a market on the signing of a free trade agreement can help retail investors gain exposure to emerging markets and changes in international trade. Check out their website at https://kalshi.com.
Suno is a music startup that allows individuals to create the music they desire, with the goal of helping people find pleasure in play and discovery once again.
Organizations trust Numeric to guarantee the accuracy of their financial information, streamline the month-end closing process, and provide immediate insights. With a rating of 4.9 out of 5 on G2.
AI Proteins is a biotechnology company that focuses on the design and engineering of synthetic mini protein therapeutics. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Luma is an AI company building the future of 3D.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.